Skip to main content
SpringerLink
Log in

Rapid antidepressant effects and abuse liability of ketamine

  • Letter to Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684

    PubMed  Google Scholar 

  • Hashimoto K (2014) R-Stereoisomer of ketamine as alternative of ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci

  • Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367–377

    Article  PubMed  Google Scholar 

  • Hillhouse TM, Porter JH, Negus SS (2014) Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology (Berl). doi:10.1007/s00213-014-3451-3

    Google Scholar 

  • Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141

    Article  CAS  PubMed  Google Scholar 

  • Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143–150

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Morgan CJ, Curran HV, Independent Scientist Committee on Drugs (2012) Ketamine use: a review. Addiction 107:27–38

    Article  PubMed  Google Scholar 

  • Suzuki T, Aoki T, Kato H, Yamazaki M, Misawa M (1999) Effects of the 5-HT3 receptor antagonist ondansetron on the ketamine-and dizocilpine-induced place preferences ion mice. Eur J Pharmacol 385:99–102

    Article  CAS  PubMed  Google Scholar 

  • Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a Grant-in-Aid for Scientific Research on Innovative Areas of the Ministry of Education, Culture, Sports, Science and Technology, Japan (to K.H.).

Conflict of interest

Dr. Hashimoto is an inventor on a filed patent application on “The use of R-ketamine in the treatment of psychiatric diseases” by Chiba University. Dr. Hashimoto has served as a scientific consultant to Astellas and Taisho, and he also received the research support from Abbvie, Dainippon Sumitomo, Otsuka, and Taisho. Dr. Chun Yang reports no biomedical financial interests or potential conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan

    Chun Yang & Kenji Hashimoto

Authors
  1. Chun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Hashimoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, C., Hashimoto, K. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231, 2041–2042 (2014). https://doi.org/10.1007/s00213-014-3543-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3543-0

Keywords

Search

Navigation